Vertex Pharmaceuticals will soon try to commercialize another medicine. The new therapy targets the same market as four of its other products. Using a priority review voucher is an expensive choice, ...
Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators said they didn’t see a path forward for broad use of its pill in treating a ...
Vertex Pharmaceuticals VRTX announced that its triple combination cystic fibrosis (CF) therapy, Kaftrio,has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) ...
Company shares surged in after-market trading on results for a drug Vertex acquired in a multibillion-dollar deal and sees as ...
Feb 5 (Reuters) - The U.S. Food and Drug Administration has denied the expanded use of Vertex Pharmaceutical Inc's bestseller, Kalydeco, in certain cystic fibrosis patients, the company said on Friday ...
PARIS, July 24 (Reuters) - Google Cloud (GOOGL.O), opens new tab will use Mistral AI's Codestral artificial intelligence model for Google's Vertex AI service, Google Cloud said on Wednesday. WHY IT'S ...
Orum to receive a $15 million upfront payment and up to $310 million in potential option fees and milestone payments per target plus tiered royalties Following the research period for each target, ...
Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for controversial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results